As previously reported, effective December 7, 2022, Sunshine Biopharma, Inc. entered into a research agreement with the Jewish General Hospital (?JGH?), Montreal, Canada, to conduct IND-enabling studies of the Company?s anti-cancer drug, Adva-27a. In August 2023, the Company was advised by JGH that the lab results on testing of the Adva-27a molecule were not favorable. After conclusion of an internal review of the lab results, on November 2, 2023, the Company provided notice to JGH of its termination of the Research Agreement, which will become effective on December 2, 2023, pursuant to the terms of the Research Agreement.

The Company has now paused the IND-enabling studies of Adva-27a pending a review of the possibility of chemical modification of the compound to address the suboptimal performance of the molecule in certain studies.